Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Drugs For Lupus Nephritis Are Headed For US FDA Review

Executive Summary

Two drugs that would be the first for lupus nephritis are on the doorstep of the US FDA, a novel drug voclosporin from Aurinia Pharmaceuticals and Benlysta from GlaxoSmithKline.

You may also be interested in...



Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.

Keeping Track: Myovant, Almirall, MacroGenics Nab Novel Approvals; Novartis’ Inclisiran Delayed

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

GSK's Eyes Benlysta Expansion With First US FDA Lupus Nephritis Approval

The new indication paves the way for Benlysta in a new patient population, as well as expansion in systemic lupus erythematosus, US specialty unit head Sheri Mullen said.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel